Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and ... looking statements” within the meaning of Section 27A of ...

Approximately 75 percent of the patients that have been enrolled in the trial to date have triple-negative breast cancer ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

at 07:00 Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS) Medicenna Therapeutics ...

Fred Hutch Cancer Center brought together a host of experts on November 2 to share tips, tools, resources and strategies for ...

Kathy Bates, 76, is speaking out about the reason she chose to forgo reconstruction surgery after getting a double mastectomy ...

Kathy Bates explained her decision not to have reconstruction surgery after her 2012 breast cancer diagnosis and double ...

ENOSBURG FALLS – With October wrapped up, the Jolley breast cancer fundraiser is officially over. This year, the Enosburg ...

Kathy Bates is opening up about her decision to forgo reconstruction surgery after undergoing a double mastectomy following a ...